Factors associated with repeated use of epinephrine for the treatment of anaphylaxis

Veena Manivannan, Ronna L. Campbell, Fernanda Bellolio, Latha G. Stead, James T C Li, Wyatt W. Decker

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: Studies looking at the use of repeated doses of epinephrine in patients experiencing anaphylaxis are limited. Objective: To determine which patients are most likely to receive repeated doses of epinephrine during anaphylaxis management. Methods: A population-based study with medical record review was conducted. All patients seen during the study period who met the criteria for the diagnosis of anaphylaxis were included. Results: The cohort included 208 patients (55.8% female). Anaphylaxis treatment included epinephrine in 104 patients (50.0%). Repeated doses were used in 27 patients (13.0%), 13 (48.1%) of them female. The median age of those who received repeated doses was 18.9 (interquartile range, 10-34) years vs 31.1 (interquartile range, 15-41) years for those who did not receive repeated doses (P = .06). The inciting agents were food (29.6%), insects (11.1%), medications (22.2%), others (7.4%), and unknown (29.6%). Patients who received repeated doses were more likely to have wheezing (P = .03), cyanosis (P = .001), hypotension and shock (P = .03), stridor and laryngeal edema (P = .007), nausea and emesis (P = .04), arrhythmias (P < .01), and cough (P = .04) and less likely to have urticaria (P=.049). They were more likely to be admitted to the hospital than patients who did not receive repeated doses (48.2% vs 15.6%; P < .001). There was no significant difference in the history of asthma between patients who received repeated doses and those who did not (P = .17). Conclusions: Of the patients, 13.0% received repeated epinephrine doses. Patients were younger and were likely to present with wheezing, cyanosis, arrhythmias, hypotension and shock, stridor, laryngeal edema, cough, nausea, and emesis and less likely to have urticaria. A history of asthma did not predict use of repeated doses of epinephrine. Our results help identify high-risk patients who may benefit from carrying more than 1 dose of epinephrine.

Original languageEnglish (US)
Pages (from-to)395-400
Number of pages6
JournalAnnals of Allergy, Asthma and Immunology
Volume103
Issue number5
DOIs
StatePublished - Nov 2009

Fingerprint

Anaphylaxis
Epinephrine
Respiratory Sounds
Therapeutics
Laryngeal Edema
Cyanosis
Urticaria
Cough
Hypotension
Nausea
Vomiting
Cardiac Arrhythmias
Shock
Asthma
Medical Records
Insects
History

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Factors associated with repeated use of epinephrine for the treatment of anaphylaxis. / Manivannan, Veena; Campbell, Ronna L.; Bellolio, Fernanda; Stead, Latha G.; Li, James T C; Decker, Wyatt W.

In: Annals of Allergy, Asthma and Immunology, Vol. 103, No. 5, 11.2009, p. 395-400.

Research output: Contribution to journalArticle

Manivannan, Veena ; Campbell, Ronna L. ; Bellolio, Fernanda ; Stead, Latha G. ; Li, James T C ; Decker, Wyatt W. / Factors associated with repeated use of epinephrine for the treatment of anaphylaxis. In: Annals of Allergy, Asthma and Immunology. 2009 ; Vol. 103, No. 5. pp. 395-400.
@article{7ec3a5297c7c46b2be1268428798bcde,
title = "Factors associated with repeated use of epinephrine for the treatment of anaphylaxis",
abstract = "Background: Studies looking at the use of repeated doses of epinephrine in patients experiencing anaphylaxis are limited. Objective: To determine which patients are most likely to receive repeated doses of epinephrine during anaphylaxis management. Methods: A population-based study with medical record review was conducted. All patients seen during the study period who met the criteria for the diagnosis of anaphylaxis were included. Results: The cohort included 208 patients (55.8{\%} female). Anaphylaxis treatment included epinephrine in 104 patients (50.0{\%}). Repeated doses were used in 27 patients (13.0{\%}), 13 (48.1{\%}) of them female. The median age of those who received repeated doses was 18.9 (interquartile range, 10-34) years vs 31.1 (interquartile range, 15-41) years for those who did not receive repeated doses (P = .06). The inciting agents were food (29.6{\%}), insects (11.1{\%}), medications (22.2{\%}), others (7.4{\%}), and unknown (29.6{\%}). Patients who received repeated doses were more likely to have wheezing (P = .03), cyanosis (P = .001), hypotension and shock (P = .03), stridor and laryngeal edema (P = .007), nausea and emesis (P = .04), arrhythmias (P < .01), and cough (P = .04) and less likely to have urticaria (P=.049). They were more likely to be admitted to the hospital than patients who did not receive repeated doses (48.2{\%} vs 15.6{\%}; P < .001). There was no significant difference in the history of asthma between patients who received repeated doses and those who did not (P = .17). Conclusions: Of the patients, 13.0{\%} received repeated epinephrine doses. Patients were younger and were likely to present with wheezing, cyanosis, arrhythmias, hypotension and shock, stridor, laryngeal edema, cough, nausea, and emesis and less likely to have urticaria. A history of asthma did not predict use of repeated doses of epinephrine. Our results help identify high-risk patients who may benefit from carrying more than 1 dose of epinephrine.",
author = "Veena Manivannan and Campbell, {Ronna L.} and Fernanda Bellolio and Stead, {Latha G.} and Li, {James T C} and Decker, {Wyatt W.}",
year = "2009",
month = "11",
doi = "10.1016/S1081-1206(10)60358-4",
language = "English (US)",
volume = "103",
pages = "395--400",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "5",

}

TY - JOUR

T1 - Factors associated with repeated use of epinephrine for the treatment of anaphylaxis

AU - Manivannan, Veena

AU - Campbell, Ronna L.

AU - Bellolio, Fernanda

AU - Stead, Latha G.

AU - Li, James T C

AU - Decker, Wyatt W.

PY - 2009/11

Y1 - 2009/11

N2 - Background: Studies looking at the use of repeated doses of epinephrine in patients experiencing anaphylaxis are limited. Objective: To determine which patients are most likely to receive repeated doses of epinephrine during anaphylaxis management. Methods: A population-based study with medical record review was conducted. All patients seen during the study period who met the criteria for the diagnosis of anaphylaxis were included. Results: The cohort included 208 patients (55.8% female). Anaphylaxis treatment included epinephrine in 104 patients (50.0%). Repeated doses were used in 27 patients (13.0%), 13 (48.1%) of them female. The median age of those who received repeated doses was 18.9 (interquartile range, 10-34) years vs 31.1 (interquartile range, 15-41) years for those who did not receive repeated doses (P = .06). The inciting agents were food (29.6%), insects (11.1%), medications (22.2%), others (7.4%), and unknown (29.6%). Patients who received repeated doses were more likely to have wheezing (P = .03), cyanosis (P = .001), hypotension and shock (P = .03), stridor and laryngeal edema (P = .007), nausea and emesis (P = .04), arrhythmias (P < .01), and cough (P = .04) and less likely to have urticaria (P=.049). They were more likely to be admitted to the hospital than patients who did not receive repeated doses (48.2% vs 15.6%; P < .001). There was no significant difference in the history of asthma between patients who received repeated doses and those who did not (P = .17). Conclusions: Of the patients, 13.0% received repeated epinephrine doses. Patients were younger and were likely to present with wheezing, cyanosis, arrhythmias, hypotension and shock, stridor, laryngeal edema, cough, nausea, and emesis and less likely to have urticaria. A history of asthma did not predict use of repeated doses of epinephrine. Our results help identify high-risk patients who may benefit from carrying more than 1 dose of epinephrine.

AB - Background: Studies looking at the use of repeated doses of epinephrine in patients experiencing anaphylaxis are limited. Objective: To determine which patients are most likely to receive repeated doses of epinephrine during anaphylaxis management. Methods: A population-based study with medical record review was conducted. All patients seen during the study period who met the criteria for the diagnosis of anaphylaxis were included. Results: The cohort included 208 patients (55.8% female). Anaphylaxis treatment included epinephrine in 104 patients (50.0%). Repeated doses were used in 27 patients (13.0%), 13 (48.1%) of them female. The median age of those who received repeated doses was 18.9 (interquartile range, 10-34) years vs 31.1 (interquartile range, 15-41) years for those who did not receive repeated doses (P = .06). The inciting agents were food (29.6%), insects (11.1%), medications (22.2%), others (7.4%), and unknown (29.6%). Patients who received repeated doses were more likely to have wheezing (P = .03), cyanosis (P = .001), hypotension and shock (P = .03), stridor and laryngeal edema (P = .007), nausea and emesis (P = .04), arrhythmias (P < .01), and cough (P = .04) and less likely to have urticaria (P=.049). They were more likely to be admitted to the hospital than patients who did not receive repeated doses (48.2% vs 15.6%; P < .001). There was no significant difference in the history of asthma between patients who received repeated doses and those who did not (P = .17). Conclusions: Of the patients, 13.0% received repeated epinephrine doses. Patients were younger and were likely to present with wheezing, cyanosis, arrhythmias, hypotension and shock, stridor, laryngeal edema, cough, nausea, and emesis and less likely to have urticaria. A history of asthma did not predict use of repeated doses of epinephrine. Our results help identify high-risk patients who may benefit from carrying more than 1 dose of epinephrine.

UR - http://www.scopus.com/inward/record.url?scp=73349133347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349133347&partnerID=8YFLogxK

U2 - 10.1016/S1081-1206(10)60358-4

DO - 10.1016/S1081-1206(10)60358-4

M3 - Article

C2 - 19927537

AN - SCOPUS:73349133347

VL - 103

SP - 395

EP - 400

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 5

ER -